Health Exec: We Have No Choice But To Embrace AI
Providers who don't take advantage of AI will get "left behind," said Dr. Shantanu Gaur, founder and CEO of Allurion Technologies, during a panel discussion at INVEST Digital Health.
Newly Public Allurion Aims to Show How Med Tech Can Complement Obesity Drugs
Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Weight Loss in a Pill Device Firm Allurion Heads to NYSE via SPAC Merger
Allurion Technologies has developed a gastric balloon that does not require surgery. The merger deal taking Allurion public comes as the company continues global commercialization of its technology.
Allurion raises $27M to commercialize gastric balloon device in the U.S. and beyond
The swallowable balloon eliminates the need for endoscopy and anesthesia, reducing costs for patients – who are generally paying out of pocket.
Another startup hoping to tackle obesity using a device raises $19M
Allurion Technologies is seeking $27 million to bring its gastric balloon device, available in Europe, to the U.S. market to tackle the obesity epidemic.